Kyverna Therapeutics (KYTX)

• Market cap: $80.4M
• 1 day: 1.64%
• 5 days: -1.59%
• 1 month: -26.77%
• 3 months: -44.14%
• 6 months: -67.08%
• Year to date: -52.55%
• 1 year: -90.90%
• 5 years: -93.80%
• 10 years: -93.80%
• Sector: Healthcare
• Industry: Biotechnology

About: Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Employees: 119

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,960% more call options, than puts

Call options by funds: $206K | Put options by funds: $10K

154% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 13

1.74% more ownership

Funds ownership: 65.13% [Q3] → 66.87% (+1.74%) [Q4]

6% less funds holding

Funds holding: 93 [Q3] → 87 (-6) [Q4]

14% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 28

22% less capital invested

Capital invested by funds: $138M [Q3] → $108M (-$30.2M) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 115% upside
• Avg. target: $12 545% upside
• High target: $20 975% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 57 / 186 met price target	115% upside $4	Neutral Maintained	3 Apr 2025
Morgan Stanley Michael Ulz 20% 1-year accuracy 4 / 20 met price target	975% upside $20	Overweight Maintained	1 Apr 2025